SHANGHAI – Leaving politics aside, a Taiwanese company and a China counterpart plan to set up a $102 million joint venture to develop a dual drug, oral direct-acting antiviral treatment for chronic hepatitis C virus (HCV).
SHANGHAI – Leaving politics aside, a Taiwanese company and a China counterpart plan to set up a $102 million joint venture to develop a dual drug, oral direct-acting antiviral treatment for chronic hepatitis C virus (HCV).
HONG KONG – Shares of China Resources Pharmaceutical Group Ltd. (HK:3320) sank in their trading debut on Oct. 28 after raising about $1.8 billion in Hong Kong, making it the largest IPO from a drugmaker in Asia this year.
HONG KONG – Shares of China Resources Pharmaceutical Group Ltd. (HK:3320) sank in their trading debut on Oct. 28 after raising about $1.8 billion in Hong Kong, making it the largest IPO from a drugmaker in Asia this year.
HONG KONG – In an effort to encourage innovation and upgrade China's pharmaceutical sector, China's drug watchdog continues to target companies with weak clinical trial data. The latest example is the rejection of 30 new drug applications.
HONG KONG – In an effort to encourage innovation and upgrade China’s pharmaceutical sector, China’s drug watchdog continues to target companies with weak clinical trial data. The latest example is the rejection of 30 new drug applications.
HONG KONG – Looking to leverage the “huge opportunity” in the ever-promising markets in Asia-Pacific, Mundipharma Pharmaceutical Co. Ltd. will launch Betadine, its first consumer health product in China, over the coming quarter.
HONG KONG – Looking to leverage the "huge opportunity" in the ever-promising markets in Asia-Pacific, Mundipharma Pharmaceutical Co. Ltd. will launch Betadine, its first consumer health product in China, over the coming quarter.
